Chemotherapy-free Treatment — A New Era in Acute Lymphoblastic Leukemia?
Mené sur 63 patients atteints d'une leucémie lymphoblastique aiguë Ph+ récemment diagnostiquée (âge médian : 54 ans), cet essai de phase II évalue l'efficacité, du point de vue de la réponse moléculaire dans la moelle osseuse, de la survie globale et de la survie sans maladie, et la toxicité d'un traitement de première ligne combinant dasatinib et blinatumomab
In this issue of the Journal, Foà et al. report on an innovative approach to treat acute lymphoblastic leukemia (ALL) involving the replacement of chemotherapy with targeted therapies, including dexamethasone, the tyrosine kinase inhibitor dasatinib, and the bispecific anti-CD3 and anti-CD19 antibody blinatumomab. This new regimen is feasible, active, and safe, with very low treatment-related mortality and promising overall and disease-free survival outcomes. This is a change in the treatment approach. The use of intensive multiagent chemotherapy in children with ALL has led to a long-term cure in more than 90% of patients. (...)